The molecular characteristics of non‐small cell lung cancer in the Northern Territory's Top End

Aim Indigenous Australians with lung cancer have poorer survival than non‐Indigenous Australians. The reasons for the disparity are not fully understood and this study hypothesized that there may be a difference in the molecular profiles of tumors. The aim of this study, therefore, was to describe a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asia-Pacific journal of clinical oncology 2024-10, Vol.20 (5), p.627-633
Hauptverfasser: Downton, Teesha Dzu Fun, Wing, Kristof, Cosentino, Stevie Brooke, Karanth, Narayan V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim Indigenous Australians with lung cancer have poorer survival than non‐Indigenous Australians. The reasons for the disparity are not fully understood and this study hypothesized that there may be a difference in the molecular profiles of tumors. The aim of this study, therefore, was to describe and compare the characteristics of non‐small cell lung cancer (NSCLC) in the Northern Territory's Top End, between Indigenous and non‐Indigenous patients, and describe the molecular profile of tumors in the two groups. Methods A retrospective review was conducted of all adults with a new diagnosis of NSCLC in the Top End from 2017 to 2019. Patient characteristics assessed were Indigenous status, age, sex, smoking status, disease stage, and performance status. Molecular characteristics assessed were epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v‐raf murine sarcoma viral oncogene homolog B (BRAF), ROS proto‐oncogene 1 (ROS1), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal‐epithelial transition (MET), human epidermal growth factor receptor 2 (HER2), and programmed death‐ligand 1 (PD‐L1). Student's t‐test and Fisher's Exact Test were used in the statistical analysis. Results There were 152 patients diagnosed with NSCLC in the Top End from 2017–2019. Thirty (19.7%) were Indigenous and 122 (80.3%) were non‐Indigenous. Indigenous patients compared to non‐Indigenous patients were younger at diagnosis (median age 60.7 years versus 67.1 years, p = 0.00036) but were otherwise similar in demographics. PD‐L1 expression was similar between Indigenous and non‐Indigenous patients (p = 0.91). The only mutations identified among stage IV non‐squamous NSCLC patients were EGFR and KRAS but testing rates and overall numbers were too small to draw conclusions about differences in prevalence between Indigenous and non‐Indigenous patients. Conclusion This is the first study to investigate the molecular characteristics of NSCLC in the Top End. This is the first study to investigate the molecular characteristics of non‐small cell lung cancer in the Northern Territory's Top End.
ISSN:1743-7555
1743-7563
1743-7563
DOI:10.1111/ajco.13967